CureVac N.V. (ETR:5CV)
Germany
· Delayed Price · Currency is EUR | Market Cap | 581.85M |
| Revenue (ttm) | 65.86M |
| Net Income (ttm) | -278.43M |
| Shares Out | n/a |
| EPS (ttm) | -1.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 451,922 |
| Average Volume | 121,235 |
| Open | 2.900 |
| Previous Close | 2.618 |
| Day's Range | 2.750 - 3.150 |
| 52-Week Range | 2.110 - 4.808 |
| Beta | 2.53 |
| RSI | 44.11 |
| Earnings Date | Apr 25, 2025 |
About CureVac
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for tre... [Read more]
Financial Performance
In 2023, CureVac's revenue was 53.76 million, a decrease of -20.26% compared to the previous year's 67.42 million. Losses were -260.17 million, 4.47% more than in 2022.
Financial StatementsNews
CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions
CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit
Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech.
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
CureVac N.V. (NASDAQ: CVAC) on Thursday said the European Patent Office (EPO) confirmed the validity of CureVac’s European patent EP 3 708 668 B1 subject to amendments to specify the scope of protect...
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
CureVac N.V. CVAC on Thursday said the European Patent Office (EPO) confirmed the validity of CureVac's European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection.
European Patent Office declares CureVac mRNA patent valid
The European Patent Office declared a patent owned by CureVac , valid, after a challenge from drugmaker BioNTech , the company said on Thursday.
CureVac up 13% as court upholds validity of patent in BioNTech spat
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended formA hearing on infringement of EP 3...
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form A hearing on infringement of EP ...
EQS-News: CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
Issuer: CureVac / Key word(s): Patent CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE 27.03.2025 / 21:05 CET/CEST The issuer is solely respons...
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators
CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolioThe company holds one of th...
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators
CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio The company holds one of t...
CureVac: LexisNexis Names It a Global Innovation Leader Again!
CureVac shines again as a beacon of innovation, securing its place among the Top 100 Global Innovators for the third year running. With a vast portfolio of nearly 1,000 patents, CureVac leads the char...
EQS-News: CureVac Earns Repeat Recognition by LexisNexis as One of the World’s Top Innovators
Issuer: CureVac / Key word(s): Patent CureVac Earns Repeat Recognition by LexisNexis as One of the World’s Top Innovators 18.02.2025 / 13:03 CET/CEST The issuer is solely responsible for the content o...
Why CureVac (CVAC) Shares Are Volatile
CureVac BV (NASDAQ: CVAC) shares have been volatile over the past week, gaining some 25% to $4.23, amid increased trading volume following the U.S.’s first human death from H5N1 bird flu . What To Kn...
CureVac: Latest GBM Data Bodes Well For Next Program Check Point
CureVac recently released new clinical data. Why should investors care? Click here to find out why I am bullish on CVAC stock.
Why CureVac (CVAC) Stock Is Moving
Shares of CureVac BV (NASDAQ: CVAC) fell by 12.3% to $4.10 Wednesday afternoon. The pullback could be due to profit-taking after Tuesday's strong gains , which were fueled by heightened concerns over...
Vaccine makers’ shares jump after bird flu death in US
Moderna, Pfizer, CureVac and Novavax register gains as health agency stresses risk to public ‘remains low’
CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript
CureVac reports Q3 results
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increase...
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increas...
CureVac Unveils Q3 2024 Financials & Key Business Updates
CureVac is making strategic strides with a €400 million boost from GSK, advancing its innovative cancer and vaccine programs, while streamlining operations for future growth and efficiency. Jetzt den ...
Earnings Scheduled For November 12, 2024
Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ: TIGR) is likely to report quarterly earnings at $0.13 per share on revenue of $98.00 million. • PLDT (NYSE: PHI) is likely to report...
Insights into CureVac's Upcoming Earnings
CureVac (NASDAQ: CVAC) is gearing up to announce its quarterly earnings on Tuesday, 2024-11-12. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based o...